Breaking News

J&J Sues HRSA for Blocking Controversial 340B Rebate Model

J&J is suing the federal government to implement the drugmaker's controversial 340B rebate proposal.
Johnson & Johnson (J&J) earlier today sued the federal government to establish a 340B rebate model, marking the latest escalation [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Arkansas Officials, Providers Urge Supreme Court to Deny PhRMA’s Appeal to Overturn 340B Contract Pharmacy Access Law

Attorneys for the state of Arkansas and local providers argued the Supreme Court should not take up PhRMA's appeal to overturn a state 340B law.
Arkansas state officials and providers are urging the U.S. Supreme Court not to take up a drug industry trade group’s [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

State Contract Pharmacy Lawsuit Weekly Roundup: Updates in West Virginia, Missouri, Kansas

Key briefs were filed this week in state contract pharmacy litigation in West Virginia, Missouri and Kansas.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Lilly Backs Sanofi Lawsuit Seeking HRSA 340B Records, Argues Contract Pharmacy Agreements Violate 340B Statute

Eli Lilly has filed an amicus brief in support of Sanofi's lawsuit seeking 340B contract pharmacy agreements from HRSA.
Eli Lilly is backing Sanofi’s lawsuit to compel the federal government to release all 340B contract pharmacy agreements, arguing that [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

BI Tightens Contract Pharmacy Restrictions for All Covered Entities

Boehringer Ingelheim recently announced it will tighten its 340B contract pharmacy restrictions by requiring claims data submission.
Drugmaker Boehringer Ingelheim (BI) will begin requiring all 340B covered entities to submit claims data to continue accessing 340B drugs [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Eli Lilly Announces Refunds for 340B Overcharges

Eli Lilly announced that it will refund 340B covered entities that purchased certain medications following adjustments to their ceiling prices.
Eli Lilly announced that it will refund 340B covered entities that purchased certain medications following adjustments to their ceiling prices. [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Pfizer CEO Calls 340B ‘One of the Biggest Issues’ During Earnings Call Touting $17.1B in Quarterly Revenue

Pfizer CEO Albert Bourla told investors that "340B reform is something that myself and the entire pharma [industry] is setting as a priority."
Pfizer’s top executive told investors this week that the 340B program “is one of the biggest issues,” during an earnings [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Arkansas, Missouri – Oct 24

Key briefs were filed this week in state contract pharmacy litigation in Arkansas and Missouri.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Ascend, Xellia Announce Refunds for 340B Overcharges

Drugmakers Xellia Pharmaceuticals and Ascend Laboratories will refund 340B providers for some products following ceiling price recalculations.
Drugmakers Xellia Pharmaceuticals and Ascend Laboratories will refund 340B providers for some products following ceiling price recalculations, according to notices [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Kalderos to Resume Legal Battle Over HRSA’s Opposition to Drugmaker 340B Restrictions, Including Rebates

Kalderos will soon file an amended complaint in its case against HRSA before the U.S. District Court for the District of Columbia.
Kalderos, the drug industry vendor behind two 340B claims data submission platforms which support 340B rebates, will file an updated [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live